Immatics NV, a clinical-stage biopharmaceutical company, is focused on the discovery and development of T-cell receptor (TCR)-based immunotherapies for cancer treatment in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACTs) and bispecific antibody-like TCRs. Its ACTengine product candidates are in Phase I clinical trials, including IMA201 which targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 which targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 which targets antigen preferentially expressed in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an antitumor therapy, which is in preclinical studies that targets tumor stromal cells. The company’s TCR Bispecifics product candidates, which are in preclinical studies, include IMA401, a testicular cancer antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It is also developing IMA101, a multi-target precision immunotherapy; and IMA301, an allogeneic cell therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop new adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple adoptive cell therapies based on T cells and TCRs; Celgene Switzerland LLC to develop new adoptive cell therapies targeting multiple cancers; Genmab A/S to develop bispecific T-cell-engaging immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics NV is headquartered in Tübingen, Germany. Genmab A/S to develop bispecific T-cell-engaging immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics NV is headquartered in Tübingen, Germany. Genmab A/S to develop bispecific T-cell-engaging immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics NV is headquartered in Tübingen, Germany.
You want to buy shares of Immatics NV (IMTX), Step by step in English
Are you looking for how to buy Immatics NV (IMTX) shares on Nasdaq safely and through a regulated and recognized broker? Are you interested in being able to invest your savings per month and have interest in the stock market? With this guide I am going to show you how you can invest in DeGiro , a reliable German investment bank with very low commissions, and how you can get your first share in Immatics NV (IMTX) (IMTX) quickly and intuitively.
The step by step is very simple :
- To begin with, we will create an account in Degiro, a platform where we will buy shares of the company Immatics NV (IMTX), (IMTX).
- Now we will add euros to execute our 1st investment in the stock market.
- When we finally see the funds, we will proceed to locate the company Immatics NV by putting its Ticker, that is, IMTX, in the search engine.
- To finish we just have to adjust the number of actions we want, the value and the type of order.
Perhaps this tutorial has been too basic for you, so I am going to show you the procedure with images of each part:
How to open your account in DeGiro.
The first step is to register in DeGiro through the following link :
It will ask us for an email, a username and a password to access, and then we will continue through the link that they have sent us by mail.
Now Degiro will ask us for necessary information in order to prove our identity . We must have the passport, national identity document or driver’s license, your telephone number and the number of the bank account that we will use to make our 1st deposit in IBAN format. If you don’t know what method this format is, you can check this simple guide article we wrote .
Once our account is approved we will have to enter money from the Enter / Withdraw option. We can proceed to make a transfer that will take 1 to 2 days, or we can make the deposit quickly using Sofort, a truly secure and reliable payment gateway.
How to buy Immatics NV (IMTX) shares via degiro
As soon as we have the money we will have the possibility of buying our 1st share. You can use the place order button that you will find at the top right or use the turn search engine and type the ticker. In the next screenshot you will see that I have used the Amazon Ticker but in your case you have to enter (IMTX), the Immatics NV ticker. As we are talking about an action, we will see that the related tickers are listed and there we will see to find Immatics NV. What is key is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on Nasdaq (NDQ) and in your case Immatics NV (IMTX) is listed on Nasdaq. This step is essential so do not make mistakes.
At the time of placing the order we are going to pay close attention to what I am going to explain to you now . We will be able to place a limit or market order. Think you plan to buy a share of Immatics NV at 11.68, but its price today is more prominent. With a limit order, we will place the value at which we plan to make the acquisition and until there are no shares selling at that value, the purchase of the share will not be carried out. With a market order, DeGiro will buy the number of shares we have suggested at the current asking price, which will be very close to today’s trading price.
In any situation it is very essential that you look at the type of organization: fixed or of the day . For example, in Spain, the stock market price is in the morning and until 1:00 p.m., and in the USA it coincides with the afternoon schedule in Spain. If the order is permanent, it will remain until it is executed, but if you prefer the “of the day” option, at the end of the trading day, if it is not executed, it will be removed from your Activity – Orders tab slopes.
I hope this detailed article has helped you to buy shares in Immatics NV. Thank you very much!
|Name||Title||Payment||exercised||Year of birth|
|Dr Harpreet Singh||CEO, MD and member of the board of directors||N/A||N/A||1974|
|Dr. Hans-George Rammensee||Co-Founder and Member of the Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Toni Weinschenk Ph.D.||Co-Founder and Chief Innovation Officer||N/A||N/A||1973|
|Mr Arnd Christ||CFO||N/A||N/A||1966|
|Mrs. Jessica Mosby Ed.D.||Senior Director of HR and Operations||N/A||N/A||N/A|
|Mr. Steffen Walter Ph.D.||Head of Technology||N/A||N/A||1976|
|Mr. Edward A. Sturchio||General Counsel||N/A||N/A||N/A|
|Ms. Anja Heuer B.Sc.||Mr. Mang. of Corp. Communications||N/A||N/A||N/A|
|Dr Carsten Reinhardt||Chief Develop. Official||N/A||N/A||1967|
|Dr Rainer Kramer||Bus Chief Officer||N/A||N/A||1964|
Recent Immatics NV events:
No events registered in Educacep